Company Status: Active As on: 06-Aug-2019
D&B Reports |
|---|
|
Compliance Report
INR 14000.00 /-
|
|
Basic Report
INR 6000.00 /-
|
|
Quick Check Report
INR 2500.00 /-
|
|
Sectoral Risk Outlook (Industry Report)
Sectoral Risk Outlook (Industry Report) Status : Unavailable
Financial Year : NA
|
Aurobindo Pharma Q3 net up 17% at ₹836 crore - BusinessLine
Aurobindo Pharma Q3 net up 17% at ₹836 crore BusinessLine
Aurobindo Pharma Ltd up for five straight sessions - Business Standard
Aurobindo Pharma Ltd up for five straight sessions Business Standard
Aurobindo Pharma Q3 Results: Net Profit Jumps Fourfold On One-Offs; Shares Drop - BloombergQuint
Buy Aurobindo Pharma, target price Rs 1100: Motilal Oswal - Economic Times
Buy Aurobindo Pharma, target price Rs 1100: Motilal Oswal Economic Times
Aurobindo Pharma Ltd Board approves interim dividend of Rs. 1.50 for FY21 - Equity Bulls
Aurobindo Pharma receives USFDA Approval for Droxidopa Capsules - Equity Bulls
Aurobindo Pharma Limited inks agreement to acquire 26% ownerships in two solar power generating companies - Equity Bulls
Q3FY21 Result Update - Aurobindo Pharma - ICICI Direct - Equity Bulls
Alprazolam Tablets Market - Aurobindo Pharma Ltd., Mylan N.V., Par Pharmaceuticals, Pfizer Inc., Taj Pharmaceu - openPR
Active Pharmaceutical Ingredients (API) Market Witness Robust Growth | AbbVie Inc.,Astrazeneca,Aurobindo Pharma Ltd.,BASF – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
Edited Transcript of ARBN.NS earnings conference call or presentation 11-Feb-21 3:00am GMT - Yahoo Finance
Asia Pacific Anti-Viral Therapies Market To See Tremendous Rise during 2019-2027 wuith Top Companies Like Aurobindo Pharma Ltd, AbbVie, GlaxoSmithKline, AstraZeneca – FLA News - FLA News
Three Weeks Later: A Relook at Aurobindo Pharma - Investing.com India
Three Weeks Later: A Relook at Aurobindo Pharma Investing.com India
Covid-19 impact on Europe Active Pharmaceutical Ingredients (API) Market Business Opportunities, Analysis and Overview by 2026 | AbbVie Inc., Astrazeneca, Aurobindo Pharma Ltd., BASF, Bayer AG – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
Impact of Covid-19 on Europe Active Pharmaceutical Ingredients (Api) Market Is Booming Worldwide | AbbVie Inc., Astrazeneca, Aurobindo Pharma Ltd., BASF, Bayer AG, Boehringer Ingelheim – The Bisouv Network - The Bisouv Network
Erectile Dysfunction Treatment Market to Exhibit a Rise by 6.2% CAGR Between 2019 to 2027 | Mylan Ph - PharmiWeb.com
Covid-19 impact on North America Active Pharmaceutical Ingredients (API) Market Key Vendors, Regional Analysis and Competitive Landscape Forecast by 2026| AbbVie Inc., Astrazeneca, Aurobindo Pharma Ltd., BASF, Bayer AG – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
BRIEF-Aurobindo Pharma Dec-Quarter Consol Net Profit Jumps - Investing.com India
BRIEF-Aurobindo Pharma Dec-Quarter Consol Net Profit Jumps Investing.com India
Cognitive Supplement Market SWOT analysis, Global Profit Growth, Share, Size outlook by 2030 | HVMN Inc., KeyView Labs Inc., Aurobindo Pharma Ltd, Quincy Bioscience - The Courier
Why Aurobindo Pharma’s Shares Ended At A Record High - BloombergQuint
Why Aurobindo Pharma’s Shares Ended At A Record High BloombergQuint
Aurobindo Pharma Shares Fall 6% After U.S. FDA Warning Letter For Subsidiary - BloombergQuint
Aurobindo Pharma Signs Pact To Sell U.S. Unit Natrol For $550 Million - BloombergQuint
Aurobindo Pharma Faces Class Action Suit In U.S. For Hiding Facts - BloombergQuint
Aurobindo Realty set to sail away with AP port EPC deal - BusinessLine
Aurobindo on firm ground but valuations reflect near-term gains - Mint
Aurobindo Pharma Q2 net profit up 26% to ₹805.65 crore - Mint
Aurobindo Pharma Ltd (ARBQY) on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
Aurobindo Pharma’s unit IV gets a reprieve; focus on new filings - Livemint
Aurobindo Pharma shares hit new high, brokerages see more upside - Mint
Aurobindo Pharma Q4 consolidated profit soars 45% on strong formulation sales - Livemint
Epidural Anesthetic Drugs and Device Market Breaking New Grounds and Touch New Level in upcoming year by| Taj Pharmaceuticals Ltd, Pfizer, Fresenius Kabi – NeighborWebSJ - NeighborWebSJ
Aurobindo remains on firm ground even as valuations reflect near-term gains - Mint
India's pharma industry reevaluating reliance on China APIs - BioWorld Online
India's pharma industry reevaluating reliance on China APIs BioWorld Online
Aurobindo Pharma calls off $1 billion deal with Sandoz after failing to get FTC nod - Livemint
Despite political tensions, Aurobindo Pharma bullish on business in China - BusinessLine
Aurobindo Pharma to make COVAXX vaccine for India and UNICEF - WION
Aurobindo Pharma gets USFDA nod for sedative drug - Moneycontrol
Aurobindo Pharma gets USFDA nod for sedative drug Moneycontrol
Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug - Moneycontrol
Aurobindo Pharma, promoters settle insider trading case with Sebi - Economic Times
Aurobindo Pharma Advances In Vaccine Race With The Covaxx Deal: Motilal Oswal - BloombergQuint
CSIR, Aurobindo Pharma Collaborate To Develop Covid-19 Vaccine - BloombergQuint
Aurobindo Pharma, Sun Pharma, Lupin Named In Lawsuit In The U.S. - BloombergQuint
Aurobindo Pharma Ltd stays supported - Business Standard
Aurobindo Pharma Ltd stays supported Business Standard
Buy Aurobindo Pharma, target price Rs 1000: Emkay Global - Economic Times
Buy Aurobindo Pharma, target price Rs 1000: Emkay Global Economic Times
Stock market update: Pharma stocks mixed; Aurobindo Pharma rises 1% - Economic Times
Aurobindo Pharma Ltd completes acquisition of 100% ownership of Eugia Pharma Specialities - Equity Bulls
Aurobindo Pharma Q2 net up 26% at ₹806 crore - BusinessLine
Aurobindo Pharma Q2 net up 26% at ₹806 crore BusinessLine
Aurobindo Pharma sued in US for hiding facts on cancer-causing agent - Business Today
Aurobindo Pharma appoints director - Business Standard
Aurobindo Pharma appoints director Business Standard
Aurobindo Pharma to acquire 100% stake in MViyeS Pharma Ventures - Business Standard
Aurobindo Pharma to acquire 100% stake in MViyeS Pharma Ventures Business Standard
Buy Aurobindo Pharma, target price Rs 985: Motilal Oswal - Economic Times
Buy Aurobindo Pharma, target price Rs 985: Motilal Oswal Economic Times
Aurobindo Pharma: Low Growth, High Valuation for Now - Moneylife
Global Erectile Dysfunction Treatment Market Industry Trends, Growth, Challenges, Share, Demand by Forecasts | Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
Aurobindo Pharma gets US FDA inspection report for Pashamylaram unit - Livemint
Aurobindo Pharma gathers pace, but new launches in US remain key - Livemint
Aurobindo, Glenmark, Lupin, Sun among 26 firms facing lawsuit in US - Livemint
Teva moves US court against Aurobindo Pharma on cancer drug Bendeka - BusinessLine
Aurobindo Pharma to invest Rs 1,500 cr in Andhra Pradesh - BusinessLine
Aurobindo Pharma Signs Pact To Sell US Unit Natrol - Techstory - Techstory
Aurobindo Pharma enters Covid-19 vaccine race - BusinessLine
Aurobindo Pharma enters Covid-19 vaccine race BusinessLine
Trending stocks: Aurobindo Pharma shares up nearly 2% - Economic Times
Trending stocks: Aurobindo Pharma shares up nearly 2% Economic Times
Will Aurobindo Pharma Be Able To Find A Cure For Its U.S. FDA Problems? - BloombergQuint
Stock market update: Nifty Pharma index climbs 3%; Aurobindo Pharma jumps 6% - Economic Times
Aurobindo’s US outlook improves but earnings may just be steady - Mint
Buy Aurobindo Pharma, target price Rs 1055: Motilal Oswal - Economic Times
Buy Aurobindo Pharma, target price Rs 1055: Motilal Oswal Economic Times
Aurobindo Pharma receives US FDA approval - Angel Broking - Equity Bulls
Aurobindo Pharma Ltd sees good buying - Business Standard
Aurobindo Pharma Ltd sees good buying Business Standard
Aurobindo Pharma weathers scrapping of Sandoz deal - BusinessLine
Aurobindo Pharma weathers scrapping of Sandoz deal BusinessLine
Buy Aurobindo Pharma, target price Rs 880: Motilal Oswal - Economic Times
Buy Aurobindo Pharma, target price Rs 880: Motilal Oswal Economic Times
Aurobindo Pharma plunges over 15% as FDA reopens probe - Economic Times
Aurobindo Pharma plunges over 15% as FDA reopens probe Economic Times
Aurobindo Pharma Ltd to increase stake in JV company Eugia Pharma Specialities Limited to 100% - Equity Bulls
Buy Aurobindo Pharma, target price Rs 1005: ICICI Securities - Economic Times
Buy Aurobindo Pharma, target price Rs 1005: ICICI Securities Economic Times
Board of Aurobindo Pharma approves transfer of biosimilar business to subsidiary - Business Standard
Aurobindo Pharma Shares Drop Most In 11 Years On U.S. FDA Observations - BloombergQuint
Buy Aurobindo Pharma, target price Rs 745: Motilal Oswal - Economic Times
Buy Aurobindo Pharma, target price Rs 745: Motilal Oswal Economic Times
Aurobindo could face pressure after USFDA action on a plant - Economic Times
Aurobindo could face pressure after USFDA action on a plant Economic Times
Aurobindo Pharma Q3 Review - Progress On New Ventures Continues: ICICI Direct - BloombergQuint
Aurobindo Pharma Ltd board approves 2nd interim dividend of Rs. 1.25 - Equity Bulls
Impact of COVID-19 on Parasomnia Treatment Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | Alpa Laboratories Ltd., Intas Pharmaceutical Ltd., Anuja Healthcare Limited, Lupin Limited, Sandoz International GmbH - NeighborWebSJ
Aurobindo Pharma Pact: CSIR-Centre Developing Proof Of Concept For Covid-19 Vaccine - BloombergQuint
Aurobindo Pharma to launch 40 new products - BusinessLine
Aurobindo Pharma to launch 40 new products BusinessLine
Aurobindo Pharma staff donate ₹3 crore to HKMCF - The Hindu
Stock market update: Pharma stocks advance; Aurobindo Pharma rises over 1% - Economic Times
AuroLife Pharma LLC receives warning letter from USFDA for Dayton, New Jersey facility - Equity Bulls
Buy Aurobindo Pharma, target price Rs 527: Nirmal Bang - Economic Times
Buy Aurobindo Pharma, target price Rs 527: Nirmal Bang Economic Times
Aurobindo Pharma gets US FDA voluntary action notice for Hyderabad unit-VIII - Livemint
Aurobindo Pharma Derivatives Strategy - Covered Call - ICICI Securities - Equity Bulls
Healthcare CMO Market 2024: Industry Analysis, Outlook and Forecast Research Report: Top Key Players are Catalent Pharma Solution, Recipharm, Auribindo Pharma Ltd. And Boehringer Ingelheim - Express Keeper
Stock market update: Nifty Pharma index down 1%; Aurobindo Pharma sheds nearly 3% - Economic Times
Aurobindo Pharma falls over 20% on receiving USFDA observations - BusinessLine
Brokerages are Upbeat on Aurobindo Pharma, Average Target of Rs 990 - Investing.com India
Brokerages are Upbeat on Aurobindo Pharma, Average Target of Rs 990 Investing.com India
Aurobindo Pharma - Approval for 3 products under PLI Scheme - ICICI Securities - Equity Bulls
Buy Aurobindo Pharma, target price Rs 770: ICICI Direct - Economic Times
Buy Aurobindo Pharma, target price Rs 770: ICICI Direct Economic Times
Buy Aurobindo Pharma, target price Rs 560: Suruchi Kapoor - Economic Times
Buy Aurobindo Pharma, target price Rs 560: Suruchi Kapoor Economic Times
Aurobindo Pharma Shares Down 6% After Unit 12 Gets Form 483 with Six Observations - News18
Erectile Dysfunction Treatment Market Breakdown, Development and New Market Opportunities & Forecasts | Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG - NeighborWebSJ
Buy Aurobindo Pharma, target price Rs 790: HDFC Securities - Economic Times
Buy Aurobindo Pharma, target price Rs 790: HDFC Securities Economic Times
Aurobindo Pharma Ltd unit gets 14 observations - Deccan Chronicle
Aurobindo Pharma Ltd unit gets 14 observations Deccan Chronicle
CIN.
L24239TG1986PLC015190
ROC Code
RoC-Hyderabad
Date of Incorporation
26/12/1986
D&B D-U-N-S® Number
65-XXX-2092
Company Category
Company limited by Shares
Company SubCategory
Non-govt company
Class of Company
Public
Industry
MANUFACTURING
Authorised Capital( INR)
760,000,000
Paid up Capital( INR)
585,915,609
Number of Members
0
Registered Address
PLOT NO.2,MAITHRIVIHAR,BEHIND MAITHRI VANAM AMEERPET, HYDERABAD ANDHRA PRADESH TG 500038 IN
Email Id
cs@aurobindo.com
Whether Listed or not
Listed
Last AGM
30/08/2018
Last Balance Sheet
31/03/2018
Registration Number
15190
| Charge Holder Name | Assets under charge | Charge Amount | Date of Creation | Date of Modification | Status |
|---|---|---|---|---|---|
| UTI BANK LTD. | 250,000,000 | 06/09/2000 | 11/02/2005 | ||
| UTI Bank Limited | 500,000,000 | 14/12/2004 | 07/03/2005 | ||
| State Bank of Travancore | 500,000,000 | 10/09/2004 | 07/03/2005 | ||
| STATE BANK OF INDIA SAIFABAD(SIB) BRANCH | 12,500,000 | 27/10/1999 | 24/04/2006 | ||
| STATE BANK OF INDIA | 0 | 19/01/2006 | - | ||
| State Bank of India | 10,000,000 | 27/11/2003 | 23/02/2005 | ||
| State Bank of India | 8,200,000,000 | 05/06/1997 | 15/12/2014 | ||
| STATE BANK OF INDIA | 800,000,000 | 24/10/2007 | - | ||
| State Bank of Hyderabad | 12,750,000,000 | 29/11/1995 | 05/01/2015 | ||
| Standard Chartered Bank | 1,640,000,000 | 29/11/1995 | 18/02/2014 | ||
| ING Bank N V | 1,856,000,000 | 28/12/2010 | - | ||
| IFCI Limited | 1,300,000,000 | 25/05/2012 | - | ||
| IFCI Limited | 1,560,000,000 | 25/05/2012 | - | ||
| IFCI Limited | 1,645,000,000 | 28/12/2010 | - | ||
| IFCI Limited | 2,250,000,000 | 28/12/2010 | - | ||
| IDBI Bank Limited | 2,000,000,000 | 05/12/2006 | 14/09/2016 | ||
| IDBI Bank Limited | 430,000,000 | 03/01/2005 | - | ||
| ICICI Limited | 400,000,000 | 06/06/2001 | 01/10/2001 | ||
| ICICI Bank Limited | 2,050,000,000 | 26/04/2010 | 19/03/2014 | ||
| ICICI BANK LIMITED | 450,000,000 | 11/12/1995 | 01/06/2007 | ||
| HDFC Bank Ltd | 560,000,000 | 01/04/2000 | 30/07/2002 | ||
| HDFC BANK LIMITED | 1,640,000,000 | 16/02/2007 | 25/08/2014 | ||
| Export-Import Bank of India | 150,000,000 | 23/12/1999 | 15/02/2001 | ||
| Export-Import bank of india | 250,000,000 | 25/09/2001 | 25/09/2003 | ||
| Export-Import Bank of India | 4,000,000 | 05/06/2002 | 27/08/2002 | ||
| Export-Import Bank of India | 4,000,000 | 17/03/2003 | 07/07/2003 | ||
| Export-Import Bank of India | 5,000,000 | 20/12/2003 | 21/09/2004 | ||
| Export-Import Bank of India | 5,000,000 | 22/01/2004 | - | ||
| Export-Import Bank of India | 500,000,000 | 15/09/2004 | 07/03/2005 | ||
| Export -Import Bank of India | 5,000,000 | 14/08/2003 | 21/09/2004 | ||
| DBS Bank Ltd | 1,640,000,000 | 08/01/2013 | 20/02/2015 | ||
| COOPERATIVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A. | 871,687,500 | 28/10/2005 | - | ||
| CANARA BANK | 0 | 27/09/2003 | - | ||
| Canara Bank | 500,000,000 | 21/09/2000 | 29/06/2017 | ||
| AXIS BANK LIMITED | 1,220,000,000 | 08/12/2005 | 31/03/2009 | ||
| Axis Bank Limited | 379,750,000 | 28/02/2011 | 22/09/2011 | ||
| ANDHRA BANK | 2,000,000,000 | 01/04/2000 | 22/06/2017 | ||
| ANDHRA BANK | 2,000,000,000 | 19/12/2008 | 02/04/2009 | ||
| ANDHRA BANK | 245,000,000 | 22/12/2000 | 31/10/2003 | ||
| ANDHRA BANK | 3,500,000 | 22/10/2003 | - | ||
| ALLAHABAD BANK | 1,800,000,000 | 17/08/2007 | 25/04/2008 | ||
| A. P. S. F. C. | 9,000,000 | 08/02/2005 | - | ||
| 3i Infotech Trusteeship Services Limited | 650,000,000 | 17/05/2008 | 10/08/2009 |
| Identification Number | Principal Names | Designation | Begin date | End date |
|---|---|---|---|---|
| 00050482 | GOVINDARAJAN NARAYANAN | Managing Director | 01/06/2012 | 12/02/2020 |
| 00523576 | KANNAN RAGUNATHAN | Additional Director | 01/06/2012 | 20/09/2018 |
| 01284132 | PENAKA VENKATA RAMPRASAD REDDY | Director | 30/12/1992 | - |
| 01284195 | KAMBAM NITYANANDA REDDY | Wholetime Director | 30/12/1992 | 06/09/2018 |
| 01284266 | METTU MADAN MOHAN REDDY | Wholetime Director | 01/01/2013 | 06/09/2019 |
| 01284320 | SIVAKUMARAN MEENAKSHISUNDERAM | Wholetime Director | 01/09/2009 | 04/10/2019 |
| 01316166 | AVNIT BIMAL SINGH | Director | 25/03/2015 | - |
| 01628013 | PENAKA SARATH CHANDRA REDDY | Wholetime Director | 27/09/2007 | 28/02/2020 |
| 01694236 | SITARAMA MURTHY MANDAVILLI | Director | 27/09/2007 | - |
| 06492679 | SAVITA MAHAJAN | Director | 16/12/2017 | - |
| XXXXXXXXXX | ADI REDDY BADDIGAM | Company Secretary | 01/06/2016 | 06/11/2019 |
| XXXXXXXXXX | SUBRAMANIAN SANTHANAM | CFO(KMP) | 01/07/2014 | 06/12/2019 |
